Key Points
- To examine the clinicopathologic and immunohistochemical characteristics of pleomorphic liposarcoma and determine the primary factors influencing patient outcomes.
- Retrospective cohort analysis of N=63 patients (35 men, 28 women; median age 63 years) evaluating tumor histology and immunohistochemical reactivity.
- Assessment of clinical interventions and survival outcomes in 48 patients with long-term follow-up (median 38 months; range 7–276 months).
- Among 48 patients followed, the local recurrence rate was 45% and the metastasis rate was 42.5%, primarily involving the lungs and pleura.
- Five-year overall survival was 57%, metastasis-free survival was 50%, and local recurrence-free survival was 48%, with disease-related mortality occurring in 35% of patients.
- Age ≥60 years, truncal location, deep tumor depth, size >5 cm, vascular invasion, and incomplete excision significantly predicted worse outcomes, whereas histologic subtype and grade did not.
Structured PICO
PPopulation63 patients with pleomorphic liposarcoma (35 men, 28 women, median age 63 years)
IInterventionSimple tumorectomy or wide excision, with or without neoadjuvant/adjuvant chemotherapy and/or radiation therapy
OOutcomeLocal recurrence rate, metastasis rate, and survival (overall, metastasis-free, and local recurrence-free)hard clinical
Pleomorphic liposarcoma is an aggressive, metastasizing neoplasm where patient age, tumor size, location, and completeness of excision are significant prognostic factors, whereas tumor grade and histology are not.